Compounds / Metabolic / Reta+Tirze Combo

Reta+Tirze Combo

Retatrutide + Tirzepatide Combination Stack
MetabolicFDA: NOT APPROVED as combination

Overview

⚠ NO CLINICAL TRIAL DATA for this combination. Reta monotherapy: 24.2% weight loss (Phase 2). Tirze monotherapy: 22.5% weight loss (SURMOUNT-1). Combining is speculative with risk of severe GI events and unknown interactions.

Mechanism of Action

Triple+dual agonist combo targeting 5 receptors: Reta = GLP-1/GIP/Glucagon triple agonist; Tirze = GLP-1/GIP dual agonist. Additive GLP-1/GIP activation + glucagon thermogenesis from retatrutide.

Molecular Profile

Molecular weight
Retatrutide ~4647 Da + Tirzepatide ~4813.5 Da

Key Research Findings

NO clinical data for combo; theoretical synergy; risk of severe GI events; retatrutide still Phase 3; experimental only.

Published Research

NEJM
Retatrutide Phase 2 obesity trial
View source
NEJM
Tirzepatide for obesity (SURMOUNT-1)
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideMazdutideBioglutide
Clinical Guidance

Research data is not a treatment plan. If you are considering Reta+Tirze Combo, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Reta+Tirze Combo? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals